Genetic Predictors of Glucocorticoid Response in Pediatric Patients With Inflammatory Bowel Diseases

Journal of Clinical Gastroenterology

Volumn 45, Issue 1, 2011, Pages e1-e7

  De Iudicibus, Sara ^a   Stocco, Gabriele ^a   Martelossi, Stefano ^b   Londero, Margherita ^b   Ebner, Egle ^c   Pontillo, Alessandra ^c   Lionetti, Paolo ^c   Barabino, Arrigo ^c   Bartoli, Fiora ^c   Ventura, Alessandro ^c   Decorti, Giuliana ^c  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

CART analysis; Genetic polymorphisms; Glucocorticoids; Inflammatory bowel disease

Indexed keywords

CARRIER PROTEIN; GLUCOCORTICOID; INTERLEUKIN 1BETA; NACHT LEUCINE RICH REPEAT PROTEIN 1; NUCLEAR PROTEIN; NUCLEAR RECEPTOR NR3C1; PREDNISONE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DRUG DOSE REDUCTION; ENTERITIS; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; CHILD; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GLUCOCORTICOIDS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; RECEPTORS, GLUCOCORTICOID; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME;

EID: 78650936254     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181e8ae93     Document Type: Article

References (50)

1. Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol. 2006;12:3204-3212
2. Castro M, Papadatou B, Baldassare M, et al. Inflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register (1996-2003). Inflamm Bowel Dis. 2008;14:1246-1252
3. Friedman S. General principles of medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33:191-208
4. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902
5. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006;4:1118-1123
6. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1124-1129
7. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373:1905-1917
8. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function*. Annu Rev Immunol. 2000;18:309-345
9. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol. 2000;109:16-22
10. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev. 2003;24:488-522
11. Van Rossum EF, Lamberts SW. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res. 2004;59:333-357
12. Van Rossum EF, Koper JW, Huizenga NA, et al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes. 2002;51:3128-3134
13. De Iudicibus S, Stocco G, Martelossi S, et al. Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease. Gut. 2007;56:1319-1320
14. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 2003;178:339-346
15. Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol. 1999;461:107-116
16. Buttgereit F, Saag KG, Cutolo M, et al. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol. 2005;34:14-21
17. Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol. 2005;17:547-557
18. Sawa Y, Oshitani N, Adachi K, et al. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease. Int J Mol Med. 2003;11:175-179
19. Pociot F, Molvig J, Wogensen L, et al. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest. 1992;22:396-402
20. Nemetz A, Nosti-Escanilla MP, Molnar T, et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics. 1999;49:527-531
21. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356:768-774
22. Jin Y, Birlea SA, Fain PR, et al. Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol. 2007;127:2558-2562
23. Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007;356:1216-1225
24. Binder V. Progress in epidemiology, quality of life and life expectancy in IBD. In: Tytgat GNJ, Bartelsman JFWM, van Deventer SJH, eds. Inflammatory Bowel Disease. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1995:27-32.
25. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53
26. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447
27. Turner D, Hyams J, Markowitz J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 2009;15:1218-1223
28. Bachmann AW, Sedgley TL, Jackson RV, et al. Glucocorticoid receptor polymorphisms and post-traumatic stress disorder. Psychoneuroendocrinology. 2005;30:297-306
29. Davies SM, Borowitz MJ, Rosner GL, et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2984-2990
30. Venables W, Ripley B. Modern Applied Statistic With S 2002 New York Springer:251-269
31. Kamdem LK, Hamilton L, Cheng C, et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2008;18:507-514
32. van Rossum EF, Koper JW, van den Beld AW, et al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol. 2003;59:585-592
33. Ukkola O, Rosmond R, Tremblay A, et al. Glucocorticoid receptor Bcl I variant is associated with an increased atherogenic profile in response to long-term overfeeding. Atherosclerosis. 2001;157:221-224
34. Buemann B, Vohl MC, Chagnon M, et al. Abdominal visceral fat is associated with a BclI restriction fragment length polymorphism at the glucocorticoid receptor gene locus. Obes Res. 1997;5:186-192
35. Di Blasio AM, van Rossum EF, Maestrini S, et al. The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin Endocrinol. 2003;59:68-74
36. Tremblay A, Bouchard L, Bouchard C, et al. Long-term adiposity changes are related to a glucocorticoid receptor polymorphism in young females. J Clin Endocrinol Metab. 2003;88:3141-3145
37. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417-426
38. Martinon F, Hofmann K, Tschopp J. The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation. Curr Biol. 2001;11:R118-R120
39. Magitta NF, Boe Wolff AS, Johansson S, et al. A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes Immun. 2009;10:120-124
40. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603
41. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29:19-20
42. Ting JP, Kastner DL, Hoffman HM. CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol. 2006;6:183-195
43. Schoultz I, Verma D, Halfvarsson J, et al. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am J Gastroenterol. 2009;104:1180-1188
44. Kummer JA, Broekhuizen R, Everett H, et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem. 2007;55:443-452
45. Raddatz D, Toth S, Schworer H, et al. Glucocorticoid receptor signaling in the intestinal epithelial cell lines IEC-6 and Caco-2: evidence of inhibition by interleukin-1beta. Int J Colorectal Dis. 2001;16:377-383
46. Kimura R, Nishioka T, Soemantri A, et al. Cis-acting effect of the IL1B C-31T polymorphism on IL-1 beta mRNA expression. Genes Immun. 2004;5:572-575
47. Wen AQ, Wang J, Feng K, et al. Effects of haplotypes in the interleukin 1beta promoter on lipopolysaccharide-induced interleukin 1beta expression. Shock. 2006;26:25-30
48. Hall SK, Perregaux DG, Gabel CA, et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum. 2004;50:1976-1983
49. Romberg-Camps MJ, Dagnelie PC, Kester AD, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009;104:371-383
50. Svec F, Yeakley J, Harrison RW III. Progesterone enhances glucocorticoid dissociation from the AtT-20 cell glucocorticoid receptor. Endocrinology. 1980;107:566-572